No evidence for an increased GVHD risk associated with post-transplant Idelalisib given for relapse of chronic lymphocytic leukemia or lymphoma: First results of a survey by the EBMT chronic malignancy and lymphoma working parties

Dreger, P. and Boumendil, A. and Koster, L. and Scheid, C. and Passweg, J. and Veelken, H. and Cahn, Y. and Collin, M. and Wilson, K. and Bazarbachi, A. and Mayer, J. and Corradini, P. and Hunault-Berger, M. and Parody Porras, R. and Gribben, J. and Bittenbring, J. and Wolff, D. and Charbonnier, A. and Cambier, N. and Montoto, S. and Kroeger, N. and Schetelig, J. (2017) No evidence for an increased GVHD risk associated with post-transplant Idelalisib given for relapse of chronic lymphocytic leukemia or lymphoma: First results of a survey by the EBMT chronic malignancy and lymphoma working parties. BONE MARROW TRANSPLANTATION, 52 (Suppl1). S424-S425. ISSN 0268-3369, 1476-5365

Full text not available from this repository.

Item Type:	Article
Subjects:	600 Technology > 610 Medical sciences Medicine
Divisions:	Medicine > Lehrstuhl für Innere Medizin III (Hämatologie und Internistische Onkologie)
Depositing User:	Petra Gürster
Date Deposited:	14 Dec 2018 13:16
Last Modified:	11 Sep 2020 05:28
URI:	https://pred.uni-regensburg.de/id/eprint/1564

Actions (login required)

View Item